309 results
Page 4 of 16
8-K
EX-10.3
qxwstcb
20 Dec 22
Departure of Directors or Certain Officers
4:15pm
8-K
EX-10.6
pdt6t 9c1t
20 Dec 22
Departure of Directors or Certain Officers
4:15pm
8-K
EX-10.5
m39bw 88pwa
20 Dec 22
Departure of Directors or Certain Officers
4:15pm
8-K
EX-10.2
za5nv4jjevms
20 Dec 22
Departure of Directors or Certain Officers
4:15pm
8-K
EX-10.4
xvghnisi9i
20 Dec 22
Departure of Directors or Certain Officers
4:15pm
8-K
EX-10.1
znx99tav00u
9 Nov 22
Entry into a Material Definitive Agreement
8:30am
8-K
EX-4.1
3d0kk limto0n
9 Nov 22
Entry into a Material Definitive Agreement
8:30am
8-K
EX-99.2
hgx7 wp51he4iwy
9 Nov 22
Entry into a Material Definitive Agreement
8:30am
424B5
qprszw 0jj8vfw
8 Nov 22
Prospectus supplement for primary offering
9:50pm
8-K
EX-99.1
g1ov r9fv10o23q
24 Oct 22
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients
9:41am
424B5
ff99q5 w71lf1keyibi9
29 Jul 22
Prospectus supplement for primary offering
5:09pm
424B5
xih79m
14 Jun 22
Prospectus supplement for primary offering
5:19pm
424B5
e2g kntvlf
14 Jun 22
Prospectus supplement for primary offering
5:18pm
UPLOAD
dmdy1n1dh x2q4esdi
2 Jun 22
Letter from SEC
12:00am